Blueprint Medicines Publishes Inaugural Corporate Responsibility Report
Blueprint Medicines (NASDAQ: BPMC) released its first Corporate Responsibility Report, emphasizing its commitment to provide sustainable value for patients with cancer and blood disorders. The report outlines activities in five key areas: patient access, research and development, employee culture, environmental sustainability, and governance. CEO Kate Haviland stated the report is a step towards transparency and accountability. The document aligns with industry standards and is developed by a multi-functional team, aiming to enhance the company’s social responsibility and integrity.
- Launch of the first Corporate Responsibility Report, enhancing transparency.
- Focus on five key domains: patient access, R&D, employee culture, environmental sustainability, and governance.
- Commitment to sustainable value for patients and communities.
- None.
-- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity --
CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today published its first Corporate Responsibility Report, highlighting its long-standing commitment to deliver sustainable value to patients with cancer and blood disorders, as well as the communities in which it operates. The report, which formalizes the company's efforts to track and report environmental, social and governance (ESG) standards and initiatives, includes summaries and performance metrics that demonstrate its purpose-driven culture and socially conscious business practices.
"Since we began operations just over a decade ago, Blueprint Medicines has become a leading precision therapy company, fueled by our profound sense of mission to drive scientific innovation and deliver life-changing treatments to patients, as well as make positive impacts on the multitude of people and communities we touch along the way," said Kate Haviland, Chief Executive Officer of Blueprint Medicines. "As we continue to grow our business, we are committed to being a force for good, and our first Corporate Responsibility Report is an important step toward this goal by providing transparency into our ongoing efforts as well as a foundation for future progress."
The report summarizes the company's activities across five interconnected domains including patient access and community engagement, research and development, employees and culture, environmental sustainability, and governance and integrity, and adopts accounting standards for the biotechnology and pharmaceuticals industry from the Sustainability Accounting Standards Board (SASB). The report was developed by a cross-functional corporate responsibility working group with direction from the Executive Team and oversight from the Nominating and Corporate Governance Committee of Blueprint Medicines' Board of Directors. It is available for download at www.BlueprintMedicines.com/Our-Responsibility.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Blueprint Medicines' strategy, goals and anticipated milestones, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this report are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this report, including, without limitation, risks and uncertainties related to the impact of the COVID-19 pandemic to Blueprint Medicines' business, operations, strategy, goals and anticipated milestones, including Blueprint Medicines' ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Blueprint Medicines' ability and plans in continuing to establish and expand a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; Blueprint Medicines' ability to successfully expand the approved indications for AYVAKIT/AYVAKYT and GAVRETO or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines' drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for AYVAKIT/AYVAKYT, GAVRETO or any drug candidates it is developing; Blueprint Medicines' ability to develop and commercialize companion diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug candidates; Blueprint Medicines' ability to successfully expand its operations, research platform and portfolio of therapeutic candidates, and the timing and costs thereof; Blueprint Medicines' ability to realize the anticipated benefits of its executive leadership transition plan; and the success of Blueprint Medicines' current and future collaborations, acquisitions, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this report represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-publishes-inaugural-corporate-responsibility-report-301587105.html
SOURCE Blueprint Medicines Corporation
FAQ
What is included in Blueprint Medicines' Corporate Responsibility Report?
When was Blueprint Medicines' Corporate Responsibility Report published?
What is the primary focus of Blueprint Medicines as indicated in the Corporate Responsibility Report?
Who is the CEO of Blueprint Medicines who commented on the report?
Where can I download the Corporate Responsibility Report from Blueprint Medicines?
